Day One Biopharmaceuticals (NASDAQ:DAWN) Insider Adam Dubow Sells 6,395 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Adam Dubow sold 6,395 shares of the firm’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $74,182.00. Following the sale, the insider directly owned 72,694 shares of the company’s stock, valued at $843,250.40. This represents a 8.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Day One Biopharmaceuticals Trading Down 2.7%

Shares of NASDAQ:DAWN opened at $11.56 on Thursday. The stock has a market capitalization of $1.19 billion, a P/E ratio of -7.61 and a beta of -1.26. The business has a 50-day moving average price of $10.34 and a two-hundred day moving average price of $8.57. Day One Biopharmaceuticals, Inc. has a 1-year low of $5.64 and a 1-year high of $13.20.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in DAWN. Mirae Asset Global Investments Co. Ltd. boosted its stake in Day One Biopharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock valued at $46,000 after buying an additional 1,029 shares during the period. Los Angeles Capital Management LLC raised its holdings in shares of Day One Biopharmaceuticals by 1.4% during the fourth quarter. Los Angeles Capital Management LLC now owns 100,314 shares of the company’s stock valued at $935,000 after acquiring an additional 1,425 shares in the last quarter. Perkins Capital Management Inc. lifted its holdings in Day One Biopharmaceuticals by 2.1% in the fourth quarter. Perkins Capital Management Inc. now owns 84,000 shares of the company’s stock worth $783,000 after buying an additional 1,750 shares during the period. CWM LLC lifted its position in Day One Biopharmaceuticals by 32.4% during the 4th quarter. CWM LLC now owns 8,373 shares of the company’s stock valued at $78,000 after acquiring an additional 2,051 shares during the period. Finally, ProShare Advisors LLC increased its stake in Day One Biopharmaceuticals by 12.9% during the 2nd quarter. ProShare Advisors LLC now owns 18,545 shares of the company’s stock valued at $121,000 after purchasing an additional 2,121 shares in the last quarter. Institutional investors own 87.95% of the company’s stock.

Trending Headlines about Day One Biopharmaceuticals

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Neutral Sentiment: Short-interest data appears to contain reporting errors and shows effectively zero short interest as of Feb. 17, producing no clear bearish or bullish signal to the market; treat this figure with caution.
• Negative Sentiment: Multiple insider sales by senior executives on Feb. 17 — CEO Jeremy Bender sold 15,459 shares at $11.60 (disclosed in an SEC Form 4), CFO Charles N. York II sold 6,065 shares at $11.60, and other insiders (Adam Dubow, Lauren Merendino, Michael Vasconcelles) also sold stock at roughly $11.60 per share. These aggregated insider reductions (some single-digit to double-digit percentage drops in individual holdings) can be perceived negatively by investors as reduced insider exposure. CEO Form 4 CFO Form 4 Insider Form 4
• Negative Sentiment: Zacks preview flags that Day One may not have the setup for an earnings beat in its upcoming report, implying analysts expect a likely negative earnings surprise — news that can weigh on sentiment ahead of the release. Zacks preview

Wall Street Analysts Forecast Growth

DAWN has been the topic of a number of research reports. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, November 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a report on Monday, December 29th. TD Cowen assumed coverage on shares of Day One Biopharmaceuticals in a research report on Tuesday, January 13th. They set a “buy” rating and a $34.00 price target on the stock. JPMorgan Chase & Co. raised their target price on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $25.71.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.